EUCTR2009-013423-31-AT进行中（未招募）不适用
Phase I/II study of lenalidomide and Cetuximab in patients with advanced solid tumors
Medizinische Universität Innsbruck, Universitätsklinik für Innere Medizin I0 个研究点开始时间: 2009年11月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Disease Characteristics:
- •1.Patients signed informed consent.
- •2.Histologically or cytologically confirmed SCCHN, NSCLC, or metastatic colorectal adenocarcinoma.
- •3.At least one unidimensionally measurable lesion.
- •4.18 – 80 years of age.
- •5.Eastern Cooperative Oncology Group (ECOG) performance status of = 1.
- •6.Female subjects of childbearing potential† must:
- •Understand that the study medication could have an expected teratogenic risk
- •Agree to use, and be able to comply with, effective contraception without interruption, 4 weeks before starting study drug, throughout study drug therapy (including dose interruptions) and for 4 weeks after the end of study drug therapy, even if she has amenorrhoea. An alternative would be an absolute and continued sexual abstinence. The following are effective methods of contraception*
- •Levonorgestrel-releasing intrauterine system (IUS)**
- •Medroxyprogesterone acetate depot
- •Tubal sterilisation
- •Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed by two negative semen analyses
- •Ovulation inhibitory progesterone-only pills (i.e., desogestrel)
- •* Combined oral contraceptive pills are not recommended. If a subject was using combined oral contraception, she must switch to one of the methods above. The increased risk of VTE continues for 4 to 6 weeks after stopping combined oral contraception.
- •Agree to have a medically supervised pregnancy test with a minimum sensitivity of 25 mIU/ml not more than 3 days before the start of study medication once the subject has been on effective contraception for at least 4 weeks. This requirement also applies to women of childbearing potential who practice complete and continued abstinence.
- •Agree to have a medically supervised pregnancy test every 4 weeks including 4 weeks after the end of study treatment, except in the case of confirmed tubal sterilization. These tests should be performed not more than 3 days before the start of next treatment. This requirement also applies to women of childbearing potential who practice complete and continued abstinence
- •7.Male subjects must
- •Agree to use condoms throughout study drug therapy, during any dose interruption and for one week after cessation of study therapy if their partner is of childbearing potential and has no contraception.
- •Agree not to donate semen during study drug therapy and for one week after end of study drug therapy.
- •8.All subjects must
- •Agree to abstain from donating blood while taking study drug therapy and for one week following discontinuation of study drug therapy.
- •Agree not to share study medication with another person and to return all unused study drug to the investigator
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Prior Treatment:
- •1.Use of chemotherapy, hormonal therapy, immunotherapy, or any other anticancer or experimental therapy within 28 days prior to study medication.
- •2.Active participation in another clinical trial.
- •3.Radiotherapy within 28 days prior to study medication.
- •4.Surgery within 28 days prior to study medication (minimally invasive procedures for the purpose of diagnosis or staging of the disease are permitted).
- •5.Prior therapy with pomalidomide (CC-4047), lenalidomide, or thalidomide.
- •Laboratory:
- •6.Absolute neutrophil count (ANC) < 1.5 x 109/L.
- •7.Platelet count < 100 x 109/L.
- •8.Creatinine Clearance < 50 mL/min.
- •9.Bilirubin > 1.5 x Upper Limit Normal (ULN) (> 2.0 x ULN in the presence of Gilbert’s Syndrome).
- •10.Serum aspartate transaminase (AST)/SGOT > 3.0 x ULN (> 5 x ULN in the presence of liver metastases).
- •Other Disease State:
- •11.Untreated, symptomatic brain metastases (brain imaging not required).
- •12.Venous thromboembolism within 6 months.
- •13.Current congestive heart failure (New York Heart Association class II-IV).
- •14.Uncontrolled hypertension
- •15.Prior malignancies within 5 years, with the exception of treated basal cell/squamous cell carcinoma of the skin or in-situ” carcinoma of the cervix or breast.
- •16.Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study or confound the ability to interpret data from the study.
- •17.Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
- •18.Pregnant or lactating females.
研究者
相似试验
Unknown
1 期
Lenalidomide and Cetuximab in Patients With Advanced Solid TumorsSolid TumorsNCT01166035Medical University Innsbruck20
进行中（未招募）
不适用
Phase I/II study of lenalidomide and gemcitabine as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. - LENAGEM-PANCAdvanced pancreatic cancerMedDRA version: 14.1Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-011793-14-SEKarolinska Institute/Hospital
进行中（未招募）
1 期
A phase I-II trial of lenalidomide, bendamustin and dexamethasone in the treatment of patients with systemic AL-amyloidosis and ineligible for stem cell transplantation - LeBenDAL-amyloidoseEUCTR2008-007125-39-ATKlinik f. Innere Med., Fachabteilung Hämatologie12
进行中（未招募）
不适用
A Phase I/II trial of lenalidomide combined with cyclophosphamide and intermediate dose dexamethasone in patients with primary (AL) systemic amyloidosis - CDR in amyloidosisEUCTR2006-007082-36-GRHellenic Oncology Cooperative Group55
招募中
不适用
A phase II study of Isatuximab and Cemiplimab in relapsed or refractory natural killer/T-cell lymphoid malignancy: Nick name – ICING studyKCT0005949Samsung Medical Center37